PureRawz today announced the publication of a 2026 research peptide overview examining several peptide-based compounds receiving attention in laboratory, analytical, and preclinical research settings.

The overview discusses retatrutide, BPC-157, ipamorelin, Pal-GHK, and broader research-use-only sourcing considerations for qualified laboratories and researchers. PureRawz said the publication is intended to summarize investigational interest, literature themes, and quality-control considerations for research compounds, not to promote consumer, human, veterinary, dietary, cosmetic, or therapeutic use.

None of the compounds discussed in the overview is approved by the U.S. Food and Drug Administration for human or veterinary use. PureRawz states that all products referenced by the company are intended strictly for research purposes and should be handled only by qualified researchers in controlled laboratory settings.

The first section of the overview examines retatrutide, a synthetic peptide studied for unimolecular activity at GLP-1, GIP, and glucagon receptors. According to the publication, retatrutide has drawn attention in metabolic research because of its tri-agonist receptor profile and its use in studies involving receptor signaling, incretin-receptor crosstalk, hepatic lipid handling, adipose tissue signaling, and substrate metabolism. The overview references published literature, including Jastreboff et al., 2023, in discussing research interest around glucagon receptor engagement and related investigational mechanisms.

PureRawz also discusses BPC-157, a synthetic fragment derived from a partial sequence of a human gastric protein. The overview describes BPC-157 as a reference compound used in laboratory models involving angiogenesis, tendon-to-bone healing models, gastrointestinal mucosal defense models, endothelial cell migration, vascularization, fibroblast activity, and collagen-organization research. The publication references Sikiric et al., 2018, in connection with preclinical discussion of VEGFR2 signaling and nitric oxide system pathways.

A separate section reviews ipamorelin, a pentapeptide studied as a selective agonist of the growth hormone secretagogue receptor. PureRawz said ipamorelin remains of interest in controlled research environments because of its receptor-selectivity profile and its use in studies involving pulsatile growth hormone release and the GH/IGF-1 axis. The overview references Raun et al., 1998, in discussing preclinical findings related to cortisol and prolactin pathway activation compared with earlier-generation growth hormone secretagogues.

The publication also includes Pal-GHK, a synthetic peptide analog derived from the naturally occurring tripeptide GHK and chemically modified with a palmitoyl group. PureRawz said the overview discusses Pal-GHK in the context of peptide engineering, lipid affinity, molecular stability, lipid-rich environments, membrane-associated research systems, structure-activity relationship studies, extracellular matrix-related protein expression studies, peptide transport, and diffusion behavior in experimental environments. The overview references literature from the Journal of Biomolecular Structure and Dynamics and the International Journal of Molecular Sciences in connection with peptide structure and lipid-associated research systems.

PureRawz said the compounds highlighted in the overview reflect several research themes heading into 2026, including multi-receptor agonism in metabolic research, selective secretagogue design in endocrine pharmacology, peptide-mediated tissue-regeneration modeling, synthetic peptide analog design, receptor-selectivity analysis, and laboratory evaluation of peptide stability.

The release also addresses supplier evaluation considerations for research-use-only compounds. PureRawz said relevant criteria for qualified laboratories may include batch-specific Certificates of Analysis, third-party purity and identity verification, methods such as HPLC and mass spectrometry, clear research-use-only labeling, transparent sourcing documentation, manufacturing information, and appropriate stability and storage guidance.

"Researchers are increasingly prioritizing traceability and batch-level verification when selecting compounds for study designs," said a PureRawz research team representative. "Our focus remains on providing third-party lab-verified materials clearly labeled for research use only."

PureRawz states that it maintains batch-specific Certificates of Analysis and third-party lab verification across its research compound catalog. The company said these materials are intended to support qualified researchers selecting compounds for in vitro, analytical, or preclinical study designs.

The full PureRawz catalog and company information are available at https://purerawz.co.

Research-Use-Only Notice

The compounds referenced in this release are not approved by the U.S. Food and Drug Administration for human or veterinary use. They are not drugs, foods, dietary supplements, cosmetics, consumer health products, or medical treatments. They are not intended for ingestion, injection, topical application, personal use, veterinary use, diagnosis, treatment, cure, mitigation, or prevention of any disease or medical condition. This release is for informational and educational purposes only and does not constitute medical, scientific, regulatory, legal, veterinary, or health advice. Research compounds should be handled only by qualified researchers in controlled laboratory settings and in accordance with applicable laws, regulations, institutional protocols, safety procedures, and ethical standards.

About PureRawz

PureRawz supplies research compounds, including peptides, to qualified laboratories and researchers. All products are intended strictly for research purposes and are not for human or veterinary use. More information is available at https://purerawz.co.

Media Contact

PureRawz

Website: https://purerawz.co

Email: support@purerawz.co